Companies › Oryzon Genomics
1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Iadademstat LSD1 inhibitor | KDM1A | Phase 1 | Acute Myeloid Leukemia, in Relapse; Accelerated Phase Myeloproliferative Neoplasm; Acute Myeloid Leukemia; Extensive Stage Lung Small Cell Carcinoma … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05546580 | Iadademstat | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oncology | Dec 2026 |
| NCT06357182 | Iadademstat | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT06661915 | Iadademstat | Phase 2 | Accelerated Phase Myeloproliferative Neoplasm | Oncology | Dec 2027 |
| NCT06287775 | Iadademstat | Phase 1 | Extensive Stage Lung Small Cell Carcinoma | Oncology | Jul 2029 |
| NCT07113691 | Iadademstat | Phase 1 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Oncology | Jan 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.